NeurAxon Closes Convertible Debenture Financing
NeurAxon, Inc., a Toronto, ON, Canada-based pharmaceutical company, has closed the sale of approximately $8.75m of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares. The financing included CTI Life Sciences Fund and existing investors Delphi Ventures, OrbiMed Advisors, LLC, Ventures West Capital, Ltd, H.I.G. Ventures, BDC […]